Somamers

Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.

Under the agreement, BMS has access to the 1,310 reagents in the public version of SomaLogic's SOMAscan assay along with a number of custom-developed reagents.

Proteomics diagnostics firm Somalogic reported data this week supporting the utility of its blood-based 13-protein panel for the detection of malignant mesothelioma.

By Adam Bonislawski
Somalogic last week published in PLoS One a study offering the first data on use of its aptamer-based Somascan platform in tissue samples.

SomaLogic will provide New England Biolabs with protein-binding reagents for use in NEB's nucleic acid amplification and PCR products.

SomaLogic will supply NEB with certain of its SomaMers technology to be incorporated into NEB's products as reversible inhibitors of thermally active DNA polymerases used in PCR.

Anticipating that NGS will become a key clinical tool in coming years, several proteomics firms and researchers are investigating it as a platform for protein biomarker detection assays that use nucleotides as capture agents, hoping to take advantage of the technology's precision and multiplexing ability.

The trials will evaluate biomarker panels for lung, colon, and prostate cancer, and may include a comparison of proteomics-based lung cancer tests from Somalogic and Celera.

Pages

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.